Indications and Usage Mechanisms of Action clinical trials
ChemicalBook > CAS DataBase List > Finasteride

Finasteride

Indications and Usage Mechanisms of Action clinical trials
Product Name
Finasteride
CAS No.
98319-26-7
Chemical Name
Finasteride
Synonyms
PROSCAR;Finasteride for peak identification;n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide;MK-906;Andozac;mk-0906;Fistide;PROSTIDE;FINASTID;Propecia
CBNumber
CB9433852
Molecular Formula
C23H36N2O2
Formula Weight
372.54
MOL File
98319-26-7.mol
More
Less

Finasteride Property

Melting point:
253 °C
alpha 
405 -59° (c = 1 in methanol)
Boiling point:
576.6±50.0 °C(Predicted)
Density 
1.065±0.06 g/cm3(Predicted)
storage temp. 
room temp
solubility 
DMSO: 32 mg/mL, soluble
form 
solid
pka
14.17±0.70(Predicted)
color 
white to beige
Water Solubility 
insoluble
Merck 
14,4082
BCS Class
1
InChIKey
DBEPLOCGEIEOCV-WSBQPABSSA-N
LogP
3.030
CAS DataBase Reference
98319-26-7(CAS DataBase Reference)
EPA Substance Registry System
1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (98319-26-7)
More
Less

Safety

Hazard Codes 
Xn,T,Xi
Risk Statements 
22-61-60-36/37/38
Safety Statements 
36/37/39-45-53-36-26-24/25
WGK Germany 
3
RTECS 
CL5245000
HS Code 
29379000
Hazardous Substances Data
98319-26-7(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H302Harmful if swallowed

Precautionary statements

P202Do not handle until all safety precautions have been read and understood.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P308+P313IF exposed or concerned: Get medical advice/attention.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
BP740
Product name
Finasteride
Purity
British Pharmacopoeia (BP) Reference Standard
Packaging
100MG
Price
$244
Updated
2024/03/01
Sigma-Aldrich
Product number
1270402
Product name
Finasteride
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
200mg
Price
$436
Updated
2024/03/01
Sigma-Aldrich
Product number
34202
Product name
Finasteride
Purity
VETRANAL
Packaging
100mg
Price
$174
Updated
2022/05/15
TCI Chemical
Product number
F0675
Product name
Finasteride
Purity
>98.0%(GC)
Packaging
200mg
Price
$59
Updated
2024/03/01
TCI Chemical
Product number
F0675
Product name
Finasteride
Purity
>98.0%(GC)
Packaging
1g
Price
$173
Updated
2024/03/01
More
Less

Finasteride Chemical Properties,Usage,Production

Indications and Usage

Finasteride is a basic drug to treat benign prostatic hyperplasia and prostatitis, a synthetic 4-nitrogen steroid hormone compound and a sex hormone drug.
It is used for benign prostatic hyperplasia, men's prostatic fat and other diseases. Finasteride is the only oral drug approved by the US Food and Drug Administration (FDA) to treat male pattern baldness.

Mechanisms of Action

Finasteride can selectively inhibit 5α-reductase, changing the conversion process of testosterone into 5α dihydrotestosterone (DHT), decreasing androgen levels in prostate cells, and prostate-specific antigens in serum, decreasing prostate swelling, and increasing urine flow rate, thereby alleviating the symptoms of prostatic hyperplasia. It acts by selectively blocking androgen stimulation of the prostate, but affects sexual function very rarely. Meanwhile, due to blocking of testosterone conversion and reduced synthesis of dihydrotestosterone, it can reduce dihydrotestosterone levels in the serum and scalp hair follicles, recovering the function of previously inhibited hair follicles, promoting hair growth and preventing loss.

clinical trials

Three controlled clinical trials were performed in men (18 to 41 years), with mild-to-moderate degrees of androgenetic alopecia. In these studies, 1879 men ingested either a 1- mg finasteride tablet or placebo tablet once daily for 12 months; after 12 months, finasteride-treated patients were switched to placebo and placebo-treated patients were switched to finasteride and they were followed for an additional 12 months. Clinical improvement was seen as early as 3 months in finasteride-treated patients and hair regrowth continued throughout the trial. Finasteride also had a stabilizing effect on hair loss, which was maintained through the second year of treatment. Hair counts in placebo-treated patients decreased during the study. Finasteride was generally well tolerated in these studies. Some men, however, experienced decreased libido, difficulty in achieving an erection, and decreased semen volume (<2% of patients in each case). These side effects resolved in 58% of the men who continued treatment and completely abated upon discontinuation of the drug.

Description

Finasteride, a novel 4-azasteroid, is a breakthrough in the treatment and control of benign prostatic hyperplasia. Mechanistically, it inhibits the prostatic-specific enzyme 5-alpha reductase, thereby decreasing the conversion of testosterone to dihydrotestosterone. It is reportedly effective in reducing urinary symptoms and prostatic volume and increasing maximal urinary flow rate. Finasteride is also being investigated as a treatment for prostatic cancer.

Chemical Properties

White or off-white crystalline powder. Soluble in chloroform, dimethyl sulfoxide, ethanol, methanol, or n-propanol. Insoluble in propylene glycol or polyethylene glycol 400. Very slightly soluble in 0.1mol/L hydrochloric acid, 0.1mol/L sodium hydroxide solution, or water.

Originator

Merck (U.S.A.)

Uses

Finasteride is an antialopecia agent that Inhibitor of 5α-reductase, the enzyme which converts testosterone to the more potent androgen, 5α-dihydrotestosterone. It is used to treatment of benign prostatic hyperplasia and androgenetic alopecia.

Definition

ChEBI: Finasteride is an aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia. It has a role as an androgen antagonist, an EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor and an antihyperplasia drug. It is an aza-steroid, a 3-oxo steroid and a delta-lactam. It derives from a hydride of a 5alpha-androstane.

Indications

Finasteride (Proscar) is a 5-reductase inhibitor that blocks the conversion of testosterone to DHT in target tissues. Since DHT is the major intracellular androgen in the prostate, finasteride is effective in suppressing DHT stimulation of prostatic growth and secretory function without markedly affecting libido. It is approved for the treatment of benign prostatic hyperplasia. Although there is usually some regression in the size of the prostate gland following administration of finasteride, clinical response may take 6 to 12 months. If the obstructive symptoms are severe, there is often not enough time to allow this compound to work.The principal adverse effects of finasteride are impotence, decreased libido, and decreased volume of ejaculate. The compound is generally well tolerated in men.

Application

Finasteride is a specific inhibitor of steroid type II 5α-reductase, an intracellular enzyme that converts testosterone to DHT. By inhibiting type II 5α-reductase, this conversion is blocked, resulting in significant decreases in serum and tissue DHT concentrations. Merck & Co. developed finasteride as an oral treatment for androgenetic alopecia after men taking finasteride (5 mg/ day) for prostate enlargement noticed regrowth of their hair. Finasteride is indicated for use in men only. Women of childbearing age cannot take finasteride because it may cause hypospadia (a developmental abnormality of the penis) in the male offspring if taken during pregnancy.

Manufacturing Process

In a flask equipped with an overhead stirrer, a nitrogen inlet, and reflux condenser was placed 840 ml of dry THF and 20.0 g of 17β-carboxylate 17β- carbomethoxy ester of 4-aza-5α-androst-1-en-3-one (synthesized according to Patent US 4,377,584, issued Mar. 22,1883, and J. Med. Chem., 29, 2298 (1986)). The resulting slurry was cooled to -5-10°C, and 27.6 mL of tbutylamine was added. A solution of ethylmagnesium bromide in THF (122 mL, 2 M) was added maintaining the temperature of the reaction mixture below 10°C. The reaction mixture was heated at reflux for 12 hours and was added to a cold (10°C) solution of 25% ammonium chloride in water. The mixture was warmed to 25°C and allowed to settle. The THF solution was separated and concentrated by atmospheric distillation to 200 mL and the product was crystallized by adding approximately 600 mL of dilute aqueous HCl. The resulting white solid was isolated by filtration and was dried at 70°C under vacuum to give 21.7 g (97% yield) 2-butyl-1-(4-carboxybenzyl)-4- chloroimidazole-5-acetic acid of finasteride. The finasteride can be purified by conventional procedures, e.g. recrystallization from methylene chloride/ethyl acetate or acetic acid/water, melting point 261°C.

brand name

Proscar

Therapeutic Function

Antineoplastic

Biological Activity

Antiandrogen that inhibits type II 5 α reductase (IC 50 = 65 nM). Suppresses the conversion of testosterone to dihydrotestosterone. Reduces prostatic dihydrotestosterone levels and prostate size in vivo . Orally active.

Biochem/physiol Actions

Selective 5α-reductase inhibitor; antiandrogen.

Pharmacokinetics

The mean oral bioavailability of finasteride is 65%, as shown in Table 45.4, and is not affected by food. Approximately 90% of circulating finasteride is bound to plasma proteins. Finasteride has been found to cross the blood-brain barrier, but levels in semen were undetectable (<0.2 ng/mL). Finasteride is extensively metabolized in the liver, primarily via CYP3A4 to two major metabolites: monohydroxylation of the t-butyl side chain, which is further metabolized via an aldehyde intermediate to the second metabolite, a monocarboxylic acid. The metabolites show approximately 20% the inhibition of finasteride for 5α-reductase. The mean terminal half-life is approximately 5 to 6 hours in men between 18 and 60 years of age and 8 hours in men older than 70 years of age. Following an oral dose of finasteride, approximately 40% of the dose was excreted in the urine as metabolites and approximately 57% in the feces. Even though the elimination rate of finasteride is decreased in the elderly, no dosage adjustment is necessary. No dosage adjustment is necessary in patients with renal insufficiency. A decrease in the urinary excretion of metabolites was observed in patients with renal impairment, but this was compensated for by an increase in fecal excretion of metabolites. Caution should be used during administration to patients with liver function abnormalities, because finasteride is metabolized extensively in the liver.

Clinical Use

The selective inhibition of the type 2 5α-reductase isozyme produces a rapid reduction in plasma DHT concentration, reaching 65% suppression within 24 hours of administering a 1-mg oral tablet (106). At steady state, finasteride suppresses DHT levels by approximately 70% in plasma and by as much as 85 to 90% in the prostate. The remaining DHT in the prostate likely is the result of type 1 5α-reductase. The mean circulating levels of testosterone and estradiol remained within their physiological concentration range. Long-term therapy with finasteride can reduce clinical significant end points of BPH, such as acute urinary retention or surgery. Finasteride is most effective in men with large prostates. Finasteride has no affinity for the AR and no androgenic, antiandrogenic, estrogenic, antiestrogenic, or progestational effects.

Veterinary Drugs and Treatments

Finasteride may be useful in treating the benign prostatic hypertrophy in canine patients. Because of the drug’s relative expense and the long duration of therapy required to see a response, its usefulness may be limited in veterinary medicine.
It may also be useful in the adjunctive treatment of adrenal disease in ferrets.

Metabolism

Finasteride is metabolised primarily via the cytochrome P450 3A4 enzyme subfamily. Following an oral dose of 14C-finasteride in man, two metabolites of the drug were identified that possess only a small fraction of the 5α-reductase inhibitory activity of finasteride. 39% of the dose was excreted in the urine in the form of metabolites (virtually no unchanged drug was excreted in the urine) and 57% of total dose was excreted in the faeces.

storage

Store at RT

References

Perifollicular fibrosis: Pathogenetic role in androgenetic alopecia; H.G. Yoo, et al.; Biol. Pharm. Bull. 29, 1246 (2006). DOI:10.1248/BPB.29.1246
Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line: J.M. Golbano, et al.; Int. J. Oncol. 32, 919 (2008) DOI:10.3892/IJO.32.4.919
Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders: S. Paba, et al.; Curr. Pharm. Des. 17, 151 (2011) DOI:10.2174/138161211795049589
Finasteride: An update of its use in the management of symptomatic benign prostatic hyperplasia (a review). M. I. Wilde, K. L. Goa, Drugs 1999, 57, 557. DOI:10.2165/00003495-199957040-00008
Finasteride: a review of its use in male pattern hair loss. K. J. McClellan, A. Markham, Drugs 1999, 57, 111. DOI:10.2165/00003495-199957010-00014
Type 1 and type 2 5α-reductase expression in the development and progression of prostate cancer (a review). L. N. Thomas, R. C. Douglas, C. B. Lazier, C. K. L. Too, R. S. Rittmaster, D. J. Tindall, Eur. Urol. 2008, 53, 244. DOI:10.1016/J.EURURO.2007.10.052

More
Less

Finasteride Suppliers

Hubei Hicks Biochemical Co., Ltd
Tel
17362916295; 17362916295
Email
w17362916295@163.com
Country
China
ProdList
4054
Advantage
58
Shanghai Norky Pharmaceutical Co., Ltd.
Tel
021-021-61075308 15216782696
Fax
021-61075308
Email
sales@norkysh.com
Country
China
ProdList
65
Advantage
58
Wuhan DKY Technology Co.,Ltd.
Tel
27-81302488 18007166089
Fax
027-81302088
Email
info@dkybpc.com
Country
China
ProdList
2024
Advantage
58
Xi'an Kono chem co., Ltd.
Tel
29-86107037-8016 15891718909
Fax
15891718909
Email
info@konochemical.com
Country
China
ProdList
218
Advantage
58
Wuhan DingCheng Biochemical Co.Ltd
Tel
027-81302558 13545255233
Email
2851686513@qq.com
Country
China
ProdList
843
Advantage
58
Wuhan Yida Pharmaceutical Co., Ltd
Tel
+86-13401188533 +86-13476102740
Email
3451936732@qq.com
Country
China
ProdList
64
Advantage
58
Jinan Junnuo Trading Co., LTD
Tel
13561750134
Email
1156455119@qq.com
Country
China
ProdList
99
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Chemvon Biotechnology Co., Ltd
Tel
021-50790412
Fax
+86-21-50790419
Email
info@chemvon.com
Country
China
ProdList
371
Advantage
57
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
4006608290; 18621169109
Fax
86-21-61259102
Email
market03@meryer.com
Country
China
ProdList
40241
Advantage
62
More
Less

View Lastest Price from Finasteride manufacturers

hebei hongtan Biotechnology Co., Ltd
Product
Finasteride 98319-26-7
Price
US $200.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
2000kg
Release date
2024-03-15
Zibo Wei Bin Import & Export Trade Co. Ltd.
Product
Finasteride 98319-26-7
Price
US $100.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
1t
Release date
2023-07-11
Changsha Staherb Natural Ingredients Co., Ltd.
Product
Finasteride 98319-26-7
Price
US $0.00/KG
Min. Order
1KG
Purity
≥98% HPLC
Supply Ability
1000KG
Release date
2023-01-03

98319-26-7, FinasterideRelated Search:


  • (5alpha,17beta)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
  • 17beta-(n-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one
  • 4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5-alpha,17-be
  • 4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta
  • l-652,931
  • mk-0906
  • n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
  • (5alpha,17beta)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
  • (5α,17β)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
  • Andozac
  • Chibrcr-Proscar
  • Firmstid:Prostide
  • 1,(5-ALPHA)-ANDROSTAN-4-AZA-3-ONE-17-BETA-(N-TERT-BUTYL-CARBOXAMIDE)
  • 17BETA-(T-BUTYLCARBAMOYL)-4-AZA-5-ALPHA-ANDROSTEN-3-ONE
  • Finastride
  • N-(1,1-Dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
  • N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
  • Finasteride,N-tert-Butyl-3-oxo-4-aza-5α-androst-1-en-17β-carboxamide, MK-906, N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
  • Finasteride (200 mg)
  • Finasteride,Proscar
  • (1S,2R,7R,10S,11S,14S,15S)-N-tert-butyl-2,15-diMethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxaMide
  • (5α,17β)-N-(1,1-DiMethylethyl)-3-oxo-
  • Finasteride API
  • N-(2-METHYL-2-PROPYL)-3-OXO-4-AZA-5ALPHA-ANDROST-1-ENE-17BETA-CARBOXAMIDE
  • MK-906
  • Fistide
  • Prosteride
  • PROSCAR
  • PROSTIDE
  • 4A,6A,11A-TRIMETHYL-2-OXO-2,4A,4B,5,6,6A,7,8,9,9A,9B,10,11,11A-TETRADECAHYDRO-1H-INDENO[5,4-F]QUINOLINE-7-CARBOXYLIC ACID TERT-BUTYLAMIDE
  • (4AR,4BS,6AS,7S,9AS,9BS,11AR)-4A,6A-DIMETHYL-2-OXO-2,4A,4B,5,6,6A,7,8,9,9A,9B,10,11,11A-TETRADECAHYDRO-1H-INDENO[5,4-F]QUINOLINE-7-CARBOXYLIC ACID TERT-BUTYLAMIDE
  • FINASTID
  • FINASTERIDE
  • N-Tert-Butyl-3-Oxo-4-Aza-5alpha-Androst-1-Ene-17be
  • Finasteride, Vetranal
  • MK-906, Proscar, Prostide, Finastid,
  • n-tert-butyl-3-oxo-4-aza-5α-androst-1-en-17β-carboxamide
  • FINASTERIDE,USP
  • (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
  • N-tert-butyl-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
  • FinasterideEdmf/Gmp
  • FinasterideEdmf/Gmp,Usp29/Ep5
  • N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide
  • (5a,17)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
  • Norandrostenediol THP Ether
  • Vitamin B1 HCL (Thiamine Hcl)
  • MK-906, N-tert-Butyl-3-oxo-4-aza-5α-androst-1-en-17β-carboxamide, N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
  • (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
  • Finasteride for peak identification
  • (1S,9aR,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
  • Finasteride, 98%, an orally active testosterone 5-alpha-reductase inhibitor
  • (1S,3aS,3bS,5aR,9aR,9bS,11aS)-9a,11a-dimethyl-N-(2-methylpropyl)-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
  • Finasteride CRS
  • 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-
  • fenasteride
  • Finasteride USP/EP/BP
  • (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a -dimethyl-2-oxo-1H,2H,4aH,4bH,5H,6H,6aH,7H,8H, 9H,9aH,9bH,10H,11H,11aH-indeno[5,4-f]quinoline- 7-carboxamide
  • Finasteride (MK-906)